4//SEC Filing
Evanson Jeff 4
Accession 0001209191-23-004118
CIK 0001649989other
Filed
Jan 18, 7:00 PM ET
Accepted
Jan 19, 8:05 PM ET
Size
9.2 KB
Accession
0001209191-23-004118
Insider Transaction Report
Form 4
Evanson Jeff
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-01-18$1.25/sh−33,738$42,173→ 1,116,230 total - Sale
Common Stock
2023-01-19$1.22/sh−103,255$125,971→ 1,012,975 total - Sale
Common Stock
2023-01-17$1.31/sh−27,162$35,582→ 1,149,968 total
Footnotes (3)
- [F1]These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from within a $1.00 range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1909 - $1.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
Related Parties
1- filerCIK 0001760511
Filing Metadata
- Form type
- 4
- Filed
- Jan 18, 7:00 PM ET
- Accepted
- Jan 19, 8:05 PM ET
- Size
- 9.2 KB